Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
Strategic acquisition aims to bolster Firefly's national security and defense capabilities, expanding its space and defense mission services.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.
Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
The combination creates the 4th largest US wafer fabrication equipment supplier, targeting an expanded $5 billion market.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Final regulatory hurdle cleared for the all-stock transaction, paving the way for an October 20 closing and a major expansion into Texas.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.